Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. (trading symbol: AADI) on January 13, 2022. The report details the entry into a material definitive agreement with Fresenius Kabi, LLC. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement rather than financial performance results.
Material Changes and Agreement Details
- Agreement Type: Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product.
- Counterparty: Fresenius Kabi, LLC.
- Product: Fyarro (sirolimus protein-bound particles for injectable suspension).
- Scope: Fresenius Kabi will manufacture, label, package, and serialize Fyarro for Aadi Bioscience.
- Duration: Effective through December 31, 2022, subject to extension by mutual written agreement.
- Geography: United States and Canada.
- Pricing: Fixed price, subject to increases under specified circumstances.
- Commitments: The Company has an obligation to purchase minimum quantities; failure to do so triggers additional payments.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary regarding future earnings. The primary risk disclosed relates to the financial obligation to purchase minimum quantities of Fyarro, with penalties for non-compliance. The full agreement text is referenced as an exhibit to be filed in a subsequent periodic report.
Investor Verification Checklist
- Verify the specific minimum quantity purchase obligations and the associated penalty structure for non-compliance.
- Review the full text of the agreement (to be filed as an exhibit) for details on pricing adjustment triggers.
- Confirm the impact of this manufacturing agreement on the company's cash burn rate and working capital requirements.
- Check subsequent filings for the actual volume of Fyarro purchased under this agreement.